SPECCRO Information

Why SPECCRO? Pharma R&D has entered an era of diminishing returns—despite massive investments, nearly 90% of drug candidates still fail in clinical trials, often due to poor efficacy or undetected toxicity. Animal models, long the standard in preclinical testing, fall short in mimicking human biology. In a pivotal shift, the FDA has begun phasing out mandatory animal testing, opening the door to modern, human-relevant science. What SPECCRO Offers SPECCRO Inc. is the first specialized research organization built to leverage traditional drug development paradigm with New Approach Methodologies (NAMs) with less reliance on animals, technology-driven solutions for preclinical efficacy and safety assessment. Designed to bridge the “Valley of Death” in translational science, SPECCRO delivers robust, human-centric in vitro datasets that improve predictivity and accelerate clinical success. How We Deliver Our platform leverages traditional paradigm and integrates advanced in vitro models with AI/ML-driven analytics, guided by seasoned scientific expertise. By translating complex data into actionable insights—through strategic technology partnerships and evidence-based interpretation, SPECCRO enables faster, more cost-effective development of safe, effective therapies. Who We Are SPECCRO is backed by a world-class scientific advisory team with over 200 years of combined experience in drug development, regulatory strategy, and translational science. We are building the future of preclinical research: human-relevant, scalable, ethical, and ready to lead.